Phosphodiesterase Inhibitors
"Phosphodiesterase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.
| Descriptor ID |
D010726
|
| MeSH Number(s) |
D27.505.519.389.735
|
| Concept/Terms |
Phosphodiesterase Inhibitors- Phosphodiesterase Inhibitors
- Phosphodiesterase Antagonists
- Phosphoric Diester Hydrolase Inhibitors
- Antiphosphodiesterases
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase Inhibitors" by people in this website by year, and whether "Phosphodiesterase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase Inhibitors" by people in Profiles.
-
Evaluation of the impacts of formulation variables and excipients on the drug release dynamics of a polyamide 6,10-based monolithic matrix using mathematical tools. AAPS PharmSciTech. 2013 Dec; 14(4):1349-59.
-
Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation. Pflugers Arch. 2006 May; 452(2):155-63.
-
Phosphodiesterase inhibition promotes the transition from compensated hypertrophy to cardiac dilatation in rats. Pflugers Arch. 2006 Jan; 451(4):526-33.
-
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol. 2005 May 09; 514(2-3):201-8.
-
A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension. S Afr Med J. 2004 Oct; 94(10):833-4.
-
Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart. 2000 Oct; 84(4):438-9.
-
CGS 21680, dibutyryl cyclic AMP and rolipram attenuate the pro-inflammatory interactions of the Pseudomonas aeruginosa -derived pigment, 1-hydroxyphenazine, with human neutrophils. Pulm Pharmacol Ther. 2000; 13(6):293-9.
-
Anti-oxidative effects of theophylline on human neutrophils involve cyclic nucleotides and protein kinase A. Inflammation. 1998 Dec; 22(6):545-57.
-
Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils. Br J Pharmacol. 1998 Jun; 124(3):547-55.